An open-label dose-finding and proof of concept study for Probody Therapeutics (Probody Tx) in subjects with metastatic or locally advanced unrespectable solid tumors and/or lymphomas

Brief description of study

If you have been diagnosed with a metastatic or advanced unresectable solid tumor or lymphoma, you may qualify for this study evaluating the investigational drug CX-072. The main goal of this Phase i study is to evaluate the effectiveness, safety and tolerability of the drug CX-072 when given alone or in combination with ipilimumab or vemurafenib in patients with metastatic or advanced unresectable solid tumors or lymphomas.

Clinical Study Identifier: s16-01257 Identifier: NCT03013491
Principal Investigator: Daniel C Cho
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.